FDA warns not to use compounded drugs in BD 3 mL, 5 mL syringes

Patient Safety Monitor Insider

August 26, 2015

Last week, the FDA issued a warning that healthcare professionals should not administer compounded or repackaged drugs stored in 3 mL and 5 mL syringes manufactured by Becton-Dickinson (BD). Drugs stored in these syringes may have a possible interaction with the rubber stopper in the syringe, possibly causing the drug to lose potency.


The syringes may be used for general purpose fluid aspiration and injection only, according to the warning.

Healthcare professionals should report any adverse events or side effects to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program:

  • Complete and submit the report online: www.fda.gov/MedWatch/report
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.


Read the full warning here.